← All diseases Rare and hereditary disorders

Hereditary ATTR amyloidosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the strongest evidence (80)Meta-analysis (11)Treatment guideline (1)Phase 3 study (30)Randomized trial (23)Systematic review (15)Clinical trial (344)Review article (146)Early study (phase 1 or 2) (7)Case report (135)Laboratory or animal study (8)Commentary or editorial (72) Studies currently recruiting participants only (35)

Filter

Publications and studies (1285)

• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Multimodality imaging for diagnosis of subclinical hereditary transthyretin cardiac amyloidosis. (2023/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment. (2023/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. (2023/03/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Imaging modalities in early cardiac transthyretin amyloidosis: who is first? (2023/03/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. (2023/03/01) ♡
• Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and diagnostic test findings. (2023/03/01) ♡
• Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. (2023/03/01) ♡
• Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant. (2023/03/01) ♡
• Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain. (2023/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Validation of an Artificial Intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records: hereditary transthyretin amyloidosis polyneuropathy as a key example. (2023/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience. (2023/03/01) ♡
• Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria. (2023/03/01) ♡
• Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy? (2023/02/01) ♡
• (99m) Technetium-pyrophosphate bone scan: A potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: A preliminary study. (2023/02/01) ♡
• Functional and structural markers of peripheral microvascular autonomic neuropathy. (2023/02/01) ♡
• Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. (2023/02/01) ♡
• Pro-inflammatory cytokine secretion induced by amyloid transthyretin in human cardiac fibroblasts. (2023/01/29) ♡
• Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study. (2023/01/01) ♡
• Treatment of acquired transthyretin amyloidosis in domino liver transplantation. (2023/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treating hereditary transthyretin amyloidosis: Present & future challenges. (2023/01/01) ♡
• Neuropathology of central nervous system involvement in TTR amyloidosis. (2023/01/01) ♡
• OPHTHALMOLOGIC INVOLVEMENT IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS. (2023/01/01) ♡
• Peripheral nerve involvement in wild-type transthyretin amyloidosis. (2023/01/01) ♡
• Microhook ab interno trabeculotomy for secondary glaucoma in patients with hereditary transthyretin amyloidosis. (2023/01/01) ♡
• Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis. (2023/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Transbronchial cryobiopsy proven amyloid diffuse cystic lung disease complicating a transthyretin mutated (ATTRm) amyloidosis: a case report. (2023/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Does Patisiran Reduce Ocular Transthyretin Synthesis? A Pilot Study of Two Cases. (2023/01/01) ♡
• Enlarged cross-sectional area in peripheral nerves in Swedish patients with hereditary V30M transthyretin amyloidosis. (2023/01/01) ♡
• Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society. (2023/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Validation of Different Diagnostic Modalities in the Detection of Cardiac Amyloidosis Among Patients With "Red Flags" (2023-12-19) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) (2023-12-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) (2023-11-18) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Cardiac Amyloidosis Registry of University Hospital Leipzig (2023-11-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Aortic Stenosis and Cardiac Amyloidosis (2023-11-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population (2023-10-19) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study) (2023-10-04) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following Chemotherapy (2023-09-28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis (2023-09-28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. 18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis (2023-09-21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Heart Failure: Don't Forget the Role of Amyloidosis (2023-08-28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Mitochondrial Function in Transthyretin Amyloidosis (2023-08-28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment (2023-07-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation (2023-06-02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis. (2023-04-19) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers (2023-04-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Identification of Clinically Significant Markers of ATTRv in Pre-symptomatic Mutation Carriers. (2023-03-31) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prevalence of Wild Type ATTR (2023-03-27) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP) (2023-02-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Multi-Modality Echocardiographic Techniques in Pathological Left Ventricular Hypertrophy Adults (2023-02-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics (2023-02-08) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.